The glucagon receptor activation at 8mg and above drives significant lipolysis and fat oxidation
NAFLD and NASH currently have no approved treatments though they impact 25% and 5% of U.S
Chen YT, Tsai TH, Yang CC, Sun CK, Chang LT, Chen HH et al (2013) Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction
This creates a patchwork system where a patient's access to treatment depends largely on their state of residence
La dosis correcta vara segn el medicamento especfico (semaglutida, dulaglutida, liraglutida, tirzepatida), la indicacin clnica, la tolerabilidad individual y la respuesta teraputica